The primary purpose of this study is to determine the safety, tolerability and pharmacokinetics of ABT-308 in healthy volunteers and patients with mild to moderate controlled asthma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
47
Safety and tolerability will be determined by evaluation of adverse events, vital sign monitoring, physical examination, electrocardiograms, lung function and laboratory assessments.
Time frame: 12 weeks after last dose
Pharmacokinetics will be determined by measuring serum concentration of ABT-308.
Time frame: 12 weeks after last dose
Immunogenicity will be determined by measuring serum concentrations of anti-ABT-308 antibodies.
Time frame: 12 weeks after last dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Multiple SC doses x 3